Cancer patients are surviving longer thanks to breakthrough treatments like targeted therapies. With the additional longevity, however, is the responsibility to consider other health issues that may manifest, either due to treatments such as [...]
A Phase II clinical trial comparing Imatinib alternated with Regorafenib to Imatinib alone is currently underway and recruiting in Australia. The trial, sponsored by the Australasian Gastro-Intestinal Trials Group, looks to examine the feasibility of [...]
Novartis Pharmaceuticals recently received FDA approval for panobinostat, a blood cancer drug that targets multiple myeloma. This was a surprising ruling, as it was a turnaround from last year’s Oncologic Drugs Advisory Committee’s 5-2 [...]
On January 24, the first GDOL (GIST Days of Learning) of 2015 brought together nearly fifty GIST patients, caregivers, family members and volunteers at the University of California San Diego Medical Center. A recap [...]
A recent report from the Institute of Medicine outlines the advantages of data sharing from clinical trials. The authors state that data sharing can lead to the discovery of new treatment modalities as well [...]
A recent article in Forbes reports that although we are witnessing a time of historic breakthroughs in cancer treatments, we are lagging behind on policy breakthroughs in the development, funding and delivery of excellent cancer [...]
You may have noticed a new look for Gleevec when you refilled your 400-mg prescription.Novartis has introduced new packaging in the U.S. market that includes each individual tablet in a blister pack. This is designed [...]
In spite of some medical professionals' claims to the contrary, cancer patients rarely request unnecessary tests or treatments according to a study cited in the JAMA journal Oncology. The study was completed at three [...]
On Wednesday, February 11, the Life Raft Group’s state leaders had their first opportunity to gather virtually and discuss best strategies for bringing together and building a support community for GIST patients and caregivers [...]
The Life Raft Group is opening up the application process for our third Virtual GIST Tumor Board, date to be determined. This time we are expanding our applications to review all GIST cases from around [...]
